Does insurance cover Zepbound or Wegovy? How coverage decisions work

Some health plans cover Zepbound or Wegovy and some do not. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) states that some, but not all, insurance plans cover medications that treat overweight and obesity, and it advises contacting your insurance provider to find out whether your plan covers them ^[1]. Wegovy is the brand name for semaglutide and Zepbound is the brand name for tirzepatide. Both are among six drugs the U.S. Food and Drug Administration (FDA) has approved for long-term use in chronic weight management ^[1]. A 2024 narrative review lists lack of insurance coverage among several barriers to newer anti-obesity medications, and a 2022 Perspective described access to these agents as severely limited ^[2][3].

What the two drugs are

Semaglutide and tirzepatide are among the therapies based on glucagon-like peptide 1 receptor agonists (GLP-1RAs), and liraglutide, semaglutide and tirzepatide are FDA-approved for obesity treatment ^[4]. NIDDK describes how weight management medications work in general: some help people feel less hungry or feel full sooner, and others make it harder for the body to absorb fat from food ^[1]. Semaglutide (Wegovy) is also one of four weight management medications the FDA has approved for children ages 12 and older ^[1].

NIDDK summarises the expected effect of prescription weight management medication in adults. After 1 year, adults taking medication as part of a lifestyle program lose, on average, 3% to 12% more of their starting body weight than people in a lifestyle program without medication ^[1]. Results vary by medication and by person, and with some medications more than half of participants lose 10% or more of their starting weight ^[1]. A loss of 5% to 10% of starting weight may improve health by lowering blood sugar, blood pressure and triglyceride levels ^[1]. NIDDK adds that most weight loss takes place within the first 6 months of starting the medication ^[1].

Why coverage differs between plans

None of the sources reports how many plans cover these drugs, so this article gives no figure ^[2][3][4]. A 2024 narrative review in the BMJ named several barriers that limit access to newer anti-obesity medications ^[2]:

• clinicians' discomfort with prescribing them ^[2]
• bias and stigma around obesity ^[2]
• lack of insurance coverage ^[2]

The same review said future research is needed on the cost effectiveness of anti-obesity medications ^[2].

A 2022 Perspective in the journal Obesity presented the coverage landscape for anti-obesity medications at that time and described access to the newer agents as severely limited ^[3]. The authors drew parallels with the conditions that made expanded insurance coverage for bariatric (weight-loss) surgery possible ^[3]. They emphasised the need for additional action by the legislature and by the Centers for Medicare and Medicaid Services (CMS) to expand coverage of evidence-based obesity treatments ^[3].

A 2025 narrative review in the Journal of Obesity stated that the arrival of generic liraglutide and evolving insurance coverage are reshaping access and affordability ^[4]. These papers are two narrative reviews and a Perspective, not studies that measured coverage, so they support background on why access is uneven rather than conclusions about any particular plan ^[2][3][4].

The clinical criteria behind a prescription

NIDDK defines body mass index (BMI) as a measure of weight in relation to height. Overweight is a BMI between 25 and 30, and obesity is a BMI of 30 or greater ^[1]. NIDDK says a health care professional may prescribe a weight management medication for an adult in either of two situations ^[1]:

• a BMI of 30 or greater ^[1]
• a BMI of 27 or greater together with weight-related health problems, such as high blood pressure or type 2 diabetes ^[1]

NIDDK also says these medications are not for everyone with a high BMI, that they do not replace physical activity or healthy eating, and that studies show they work best combined with a lifestyle program ^[1]. These criteria describe when a clinician may prescribe; the sources do not describe the eligibility rules any individual plan applies ^[1][2][3][4].

Federal employees, Medicare and Medicaid

The 2022 Perspective reported a then-recent requirement from the U.S. Office of Personnel Management (OPM) for carriers in the Federal Employees Health Benefits Program (FEHB) to offer adequate coverage of FDA-approved anti-obesity medications ^[3]. That description dates from 2022, and the source does not describe current FEHB benefit terms ^[3].

The same authors called for further action by CMS and the legislature to expand coverage of evidence-based obesity treatments ^[3]. None of the sources here describes Medicare or Medicaid policy as of 2026, so this article makes no statement about current terms under those programs ^[3][4].

Treatment over time

NIDDK says how long a person needs a weight management medication depends on whether it helps them lose weight and keep it off and whether they experience serious side effects ^[1]. A person who has lost enough weight to improve their health, without serious side effects, may be advised to stay on the medication indefinitely ^[1].

NIDDK also describes an early checkpoint. A person who has not lost at least 5% of their starting weight after 12 weeks on the full dose will probably be advised to stop ^[1]. A health care professional may then change the treatment plan, consider a different weight management medication, try different lifestyle programs, change other medications that might be causing weight gain, or refer the person to a bariatric surgeon ^[1].

NIDDK tells readers that they probably will regain some weight after stopping a weight management medication, and that healthy eating and increased physical activity may help them regain less ^[1]. NIDDK lists the important factors to consider when choosing a medication ^[1]:

• the likely benefits of weight loss ^[1]
• the medication's possible side effects ^[1]
• current health issues and other medications ^[1]
• family medical history ^[1]
• cost ^[1]

Where AthleticsMD fits

AthleticsMD offers ShredRx, a physician-guided medical weight loss service, along with functional and preventive medicine, at locations in Columbia and Laurel/Fort Meade, Maryland ^{[AthleticsMD]}.

NIDDK describes choosing a medication to treat overweight or obesity as a decision between a person and their health care professional ^[1]. That holds whichever practice a reader uses; a decision about a specific drug is one to make with a clinician ^[1].

How to decide

NIDDK advises asking the insurance provider directly whether a plan covers these medications ^[1]. Questions that a plan, a benefits office or a clinician can answer include:

• Does my plan cover semaglutide (Wegovy) or tirzepatide (Zepbound) for chronic weight management, and is one listed on different terms from the other? ^[1]
• What eligibility criteria does the plan use, and how do they compare with NIDDK's thresholds of a BMI of 30 or greater, or 27 or greater with weight-related health problems? ^[1]
• Does the plan ask for evidence that I am taking part in a lifestyle program alongside the medication, which NIDDK says is how these drugs work best? ^[1]
• What does the plan require to continue coverage, and does it refer to weight-loss response, such as the 12-week, 5% checkpoint NIDDK describes? ^[1]
• If I have FEHB coverage, what does my carrier's current benefit booklet say about FDA-approved anti-obesity medications? ^[3]
• If coverage is denied or ends, which other options does the plan cover, such as other FDA-approved weight management medications or a referral to a bariatric surgeon? ^[1][3]
• Given that NIDDK says some weight regain is probable after stopping, what would my clinician recommend if coverage changed partway through treatment? ^[1]
• Once my out-of-pocket cost is known, how does it weigh against the likely benefits, side effects, current health issues, other medications and family history that NIDDK lists? ^[1]